The Effect of A1 Adenosine Receptor in Diabetic Megalin Loss with Caspase-1/IL18 Signaling [Corrigendum]
Tian D, Shi X, Zhao Y, et al. Diabet Metab Syndr Obes. 2019;12:1583– 1596.The authors of this paper have advised that Figures 5 and 6 are incorrect. The authors provided only one actin control for each treatment. However, their different target proteins had their own matched actin from the...
Main Authors: | Tian D, Shi X, Zhao Y, Peng X, Zou L, Xu L, Ma Y, Wen Y, Faulhaber-Walter R, Chen L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-03-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Subjects: | |
Online Access: | https://www.dovepress.com/250600-dmso-corrigendum-the-effect-of-a1-adenosine-receptor-in-diabeti-peer-reviewed-article-DMSO |
Similar Items
-
The effect of A1 adenosine receptor in diabetic megalin loss with caspase-1/IL18 signaling
by: Tian D, et al.
Published: (2019-08-01) -
Urinary megalin levels in patients with type 2 diabetic nephropathy and its correlation with renal function
by: Sudharshan Jagennath, et al.
Published: (2024-01-01) -
Participation of OCRL1, and APPL1, in the expression, proteolysis, phosphorylation and endosomal trafficking of megalin: Implications for Lowe Syndrome
by: Lisette Sandoval, et al.
Published: (2022-10-01) -
Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study
by: Satoshi Shoji, et al.
Published: (2019-12-01) -
Proximal Tubular Expression Patterns of Megalin and Cubilin in Proteinuric Nephropathies
by: Jia Sun, et al.
Published: (2017-07-01)